


IN THE CLAIMS

Please amend the claims as follows:


Claim 1 (Currently Amended): A compound of the formula (I):



wherein

~~R¹ is acyl;~~


~~X is a bivalent residue derived from optionally substituted thiazole;~~



wherein the 1,3-thiazole ring is optionally substituted at the 5-position;

Y is a bond, lower alkylene, lower alkenylene or -CONH-; and

Z is a group of the formula:




wherein R² is a group of the formula: -A-B-D-E

wherein A is a bond, lower alkylene, -NH- or -SO₂-;

B is a bond, lower alkylene, -CO- or -O-;

D is a bond, lower alkylene, -NH- or -CH₂NH-; and

E is optionally protected amino, -N=CH₂,



wherein

Q is -S- or -NH-; and


R³ is hydrogen, lower alkyl, lower alkylthio or

-NH-R⁴ wherein R⁴ is hydrogen, -NH₂ or


lower alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 2 (Original): The compound of claim 1, wherein Z is a group of the formula:




wherein R² is a group of the formula:




(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen, -NH₂ or lower alkyl); -NH₂; -CH₂NH₂; -CH₂ONH₂;

-CH₂ON=CH₂;




or a pharmaceutically acceptable salt thereof.

Claim 3 (Original): The compound of claim 2, wherein R² is a group of the formula:



(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen or lower alkyl); -CH₂NH₂; -CH₂ONH₂; -CH₂ON=CH₂;



or a pharmaceutically acceptable salt thereof.

Claim 4 (Original): The compound of any of claims 1 to 3, wherein R¹ is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

Claim 5 (Original): The compound of claim 1, wherein the compound is

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide, or


N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide,

or a pharmaceutically acceptable salt thereof.

Claim 6 (Canceled).

Claim 7 (Original): A pharmaceutical composition, which comprises, as an active ingredient, the compound of claim 1 or a pharmaceutically acceptable salt thereof.


Claim 8 (Withdrawn: Currently Amended): A method for producing a compound of the formula (I):



wherein

R^1 is acyl;


~~X is a bivalent residue derived from optionally substituted thiazole;~~



wherein the 1,3-thiazole ring is optionally substituted at the 5-position;

Y is a bond, lower alkylene, lower alkenylene or -CONH-; and

Z is a group of the formula:




wherein R^2 is a group of the formula: -A-B-D-E

wherein A is a bond, lower alkylene, -NH- or -SO₂-;

B is a bond, lower alkylene, -CO- or -O-;

D is a bond, lower alkylene, -NH- or -CH₂NH-; and

E is optionally protected amino, -N=CH₂,



wherein

Q is -S- or -NH-; and


R^3 is hydrogen, lower alkyl, lower alkylthio or

-NH- R^4 wherein R^4 is hydrogen, -NH₂ or


lower alkyl;

or a pharmaceutically acceptable salt thereof, which method comprises at least one step selected from the group consisting of (i) to (v):

(i) reacting Compound (1):




with Compound (2):




wherein L_1 is a leaving group and Z is as defined above, or a salt thereof;

(ii) reacting Compound (3): $\text{H}_2\text{N}-\text{X}-\text{Z}$




wherein ~~X and Z are~~ is as defined above and the 1,3-thiazole ring is optionally substituted at

the 5-position, or a salt thereof with Compound (4): R^+-L_2-



wherein ~~R^+ is as defined above~~ and L_2 is a leaving group;


(iii) reacting Compound (6): $\text{R}^+-\text{NH}-\text{X}-\text{CHO}$



wherein the 1,3-thiazole ring is optionally substituted at the 5-position ~~R^+ and X are as defined above,~~ or a salt thereof with Compound (7): L_3-CH_2-Z


wherein L_3 is a leaving group and Z is as defined above, or a salt thereof;

(iv) reduction of Compound (10):




~~$R^+-NH-X-(lower\ alkenylene)-Z$~~

wherein R^+ , ~~X~~ and Z are is as defined above and the 1,3-thiazole ring is optionally substituted at the 5-position, or a salt thereof to Compound (11): ~~$R^+-NH-X-(lower\ alkylene)-Z$~~



wherein R^+ , ~~X~~ and Z are is as defined above and the 1,3-thiazole ring is optionally substituted at the 5-position, or a salt thereof; and

(v) reacting Compound (12): ~~$R^+-NH-X-COOH$~~



wherein the 1,3-thiazole ring is optionally substituted at the 5-position or a reactive derivative thereof, ~~wherein R¹ and X are as defined above,~~ or a salt thereof with Compound (13): L₄-NH-Z

wherein L⁴ is a hydrogen atom or a protecting group and Z is as defined above, or a salt thereof.

Claims 9-16 (Canceled).

Claim 17 (Withdrawn: Currently Amended): A method for ~~preventing or~~ treating macular edema, which method comprises administering to a subject in need thereof a compound as claimed in claim 1 in an amount sufficient to treat said subject for macular edema.

Claim 18 (Withdrawn: Currently Amended): The method of claim 17, wherein the compound is

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide, or
N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide,
or a pharmaceutically acceptable salt thereof.

Claim 19 (Withdrawn: Currently Amended): A method for ~~preventing or~~ treating a VAP-1 associated disease, which method comprises administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a mammal.

Claim 20 (Withdrawn): The method of claim 19, wherein said VAP-1 associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients), an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjögren's syndrome, Behçet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis), a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon), fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and recurrent aphthous stomatitis], a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischaemia-reperfusion injury

associated with ischemic stroke), a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease), a (chronic) skin inflammatory disease or condition (psoriasis, allergic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, pityriasis rubra pilaris), a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity), a vascular disease [atheromatous atherosclerosis, nonatheromatous atherosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM)) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure)] and macular edema (diabetic and non-diabetic macular edema).

Claim 21 (Withdrawn): The method of claim 20, wherein said VAP-1 associated disease is macular edema.

Claim 22 (Withdrawn): The method of claim 21, wherein said macular edema is diabetic macular edema.

Claim 23 (Withdrawn): The method of claim 21, wherein said macular edema is non-diabetic macular edema.

Claim 24 (New): A method of inhibiting VAP-1 in a subject in need thereof, comprising administering to the subject the compound as claimed in claim 1 in an amount sufficient to inhibit VAP-1 in the subject.

Claim 25 (New): The method of claim 24, wherein the compound is

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide, or

N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide, or a pharmaceutically acceptable salt thereof.

DISCUSSION OF THE AMENDMENTS

Claim 1 is currently amended.

Claims 2-5 and 7 are original.

Claims 6 and 9-16 are canceled.

Claim 8 and 17-19 are withdrawn and currently amended.

Claims 20-23 are withdrawn.

Claims 24 and 25 are new.

Upon entry of the amendment, Claims 1-5, 7, 8 and 17-25 will be pending with Claims 1-5, 7, 24 and 25 under active consideration.

The amendments to Claims 1 and 8 are supported by Claims 1 and 8 as originally filed.

New claims 24 and 25 are supported by original claims 9, 10, 17 and 18.

No new matter has been added by the amendments.